Abstract: Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ?3.9 when administered at the same toxin dose.

Abstract: Antibody-drug conjugates (ADCs) comprising an antibody construct that specifically binds c-Met conjugated to one or more drugs, such as the auristatin analogue, compound 1, via a linker. Also described are anti-cMet antibody constructs that have been engineered to include one or more cysteine insertion mutations with each inserted cysteine residue providing a conjugation “handle” allowing for conjugation of a drug-linker to provide an ADC. Further described are multivalent drug-linkers comprising a plurality of the auristatin analogues suitable for use in the ADCs described herein.

Abstract: A casket lid includes a lid body that extends partially over a casket body configured to receive a human body in supine position, the lid body having a first side configured to extend along a portion of a first casket body side, a second side configured to extend along a portion of a second casket body side, a first end configured to extend along a first casket body end, and an open end. A skirt assembly includes a substrate having a top edge, and further includes at least one sheet of flexible material affixed to and extending over the top edge and downward from the substrate. The sheet of flexible material extends to or below a vertical level of a lowest portion of at least one of the first side and the second side.

Abstract: Methods of treating subjects having a HER2-expressing cancer with an anti-HER2 biparatopic antibody using a 2-tiered fixed dosing regimen based on the weight of subjects being treated are described. Combination therapy with chemotherapeutic agents and/or a PD-1 inhibitor, for example an anti-PD-1 antibody, are also described.

Abstract: The invention relates to compounds or pharmaceutically acceptable salts thereof, compositions containing them, including combinations with at least one additional therapeutic agent, and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by a mycobacterium, such as tuberculosis.

Abstract: A funerary method includes disposing a deceased adult human body in supine position on an insert having side walls and end walls. The method further includes providing the insert on a tray having two end panels and a plurality of side panels affixed to a bottom panel, and inserting a first edge of a first fabric segment between a side panel of the tray and a side wall of the insert. The first fabric segment is used to cover at least a portion of a top edge of at least the first side wall of the insert and at least a portion of the deceased human body, such that the deceased human body is sufficiently visible for identification. Thereafter, the insert and the deceased human body are removed from the tray.

Abstract: A shipment package includes container blanks and lid blanks. Each container blank has a first length and is foldable into a casket container. Each container blank has first and second folded over ends. The container blanks are stacked such that the first folded over ends of the plurality of container blanks are at least partially aligned, and such that the second folded over ends of the plurality of container blanks are at least partially aligned. Each lid blank is foldable into a casket lid having at least approximately the first length, and is configured to cover an interior of the casket container. Each lid blank is folded over a widthwise fold line such that the lid blank has a length less than the first length. A first lid blank is disposed between two container blanks, and between folded over ends of one of the container blanks.

Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

Abstract: A shipment package includes container blanks and lid blanks. Each container blank has a first length and is foldable into a casket container. Each container blank has first and second folded over ends. The container blanks are stacked such that the first folded over ends of the plurality of container blanks are at least partially aligned, and such that the second folded over ends of the plurality of container blanks are at least partially aligned. Each lid blank is foldable into a casket lid having at least approximately the first length, and is configured to cover an interior of the casket container. Each lid blank is folded over a widthwise fold line such that the lid blank has a length less than the first length. A first lid blank is disposed between two container blanks, and between folded over ends of one of the container blanks.

Abstract: A casket lid includes a lid body that extends partially over a casket body configured to receive a human body in supine position, the lid body having a first side configured to extend along a portion of a first casket body side, a second side configured to extend along a portion of a second casket body side, a first end configured to extend along a first casket body end, and an open end. A skirt assembly includes a substrate having a top edge, and further includes at least one sheet of flexible material affixed to and extending over the top edge and downward from the substrate. The sheet of flexible material extends to or below a vertical level of a lowest portion of at least one of the first side and the second side.